retatrutide triple agonist glp-1 gip glucagon Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces
Description
N Engl J Med 362(9):774777 Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K (2023) SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
Christensen, L., Roager, H
[DOI] [PubMed] [Google Scholar] 294.Edfalk S., Steneberg P., Edlund H
Even with discounts and rebates offered by companies like Eli Lilly, the costs are restrictive for a large portion of the necessary population
Empagliflozin reduced the primary outcome (kidney disease progression or cardiovascular death) by 28% compared with placebo
[DOI] [PMC free article] [PubMed] [Google Scholar] 202.Talha M., Ali M.H
